We have identified two inbred mouse strains, C57BL/6J (B6) and C3H/HeJ (C3H), that differ by 40% in serum IGF-I levels. Furthermore, this difference in serum IGF-I (B6=low; C3H=high) is accompanied by a marked difference of 50% in femoral bone mineral density (BMD; B6 = low, C3H = high) and in skeletal IGF-I content. Preliminary data on F2 progeny of genetic crosses between these two strains show that serum IGF-I levels co- segregate with high or low BMD and that IGF-I accounts for nearly 40% of the variance in BMD. The distribution of serum IGF-I levels in these F2 progeny demonstrates that IGF-I is a polygenic trait that can be analyzed by quantitative trait loci (QTL) methodology. To assess the functional effects of IGF-1 on bone mass in the absence of GH regulation, we have developed C3H and B6 strains carrying the mutant gene little (lit) that result in genetic deficiency in serum GH. Preliminary data show that despite genetic GH deficiency, serum IGF-1 and BMD are significantly higher in the C3H-lit/lit compared with the B6-lit/lit. Therefore, genes in the C3H/HeJ background other than GH are exerting detectable influence on serum IGF-1 and on BMD. In this application we will test two hypothesis: 1) Serum IGF-I is a polygenic trait whose genetic components can be mapped, and 2) IGF-1 is a major determinant of bone mass in mice, acquisition and maintenance of bone mass. The two specific aims of this proposal are: 1) To map the heritable factors that control serum IGF-1 levels by utilizing QTL methodology to locate chromosomal regions with molecular markers that co-segregate with high and low serum IGF-1 in F2 progeny and in specific congenic strains of lit/lit mice; and, 2) To assess the functional relationship between IGF-1 and bone mass by measuring BMD by pQCT, bone mineral content by pDEXA, biochemical markers, and histomorphometry in F2 progeny and congenic strains of mice. From these studies, we will demonstrate that IGF-I is critical factor for the acquisition and maintenance of bone mass. In addition, we will define specific foci in addition to GH that regulate the IGF-I phenotype. These results should have wide spread implications for both understanding and treating disorders of low bone mass.
| Guntur, Anyonya R; Le, Phuong T; Farber, Charles R et al. (2014) Bioenergetics during calvarial osteoblast differentiation reflect strain differences in bone mass. Endocrinology 155:1589-95 |
| Rahman, Sima; Lu, Yalin; Czernik, Piotr J et al. (2013) Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton. Endocrinology 154:2687-701 |
| Wu, Yingjie; Sun, Hui; Basta-Pljakic, Jelena et al. (2013) Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor. J Bone Miner Res 28:1575-86 |
| Motyl, Katherine J; Bishop, Kathleen A; DeMambro, Victoria E et al. (2013) Altered thermogenesis and impaired bone remodeling in Misty mice. J Bone Miner Res 28:1885-97 |
| Smith, Spenser S; Kessler, Catherine B; Shenoy, Vikram et al. (2013) IGF-I 3' untranslated region: strain-specific polymorphisms and motifs regulating IGF-I in osteoblasts. Endocrinology 154:253-62 |
| Kawai, Masanobu; Rosen, Clifford J (2012) The insulin-like growth factor system in bone: basic and clinical implications. Endocrinol Metab Clin North Am 41:323-33, vi |
| Guntur, Anyonya R; Rosen, Clifford J (2012) Bone as an endocrine organ. Endocr Pract 18:758-62 |
| Xian, Lingling; Wu, Xiangwei; Pang, Lijuan et al. (2012) Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 18:1095-101 |
| Motyl, Katherine J; Rosen, Clifford J (2012) The skeleton and the sympathetic nervous system: it's about time! J Clin Endocrinol Metab 97:3908-11 |
| Guntur, Anyonya R; Rosen, Clifford J; Naski, Michael C (2012) N-cadherin adherens junctions mediate osteogenesis through PI3K signaling. Bone 50:54-62 |
Showing the most recent 10 out of 61 publications
